Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Purchased by Curi RMB Capital LLC

Curi RMB Capital LLC increased its position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 49.8% in the 3rd quarter, Holdings Channel.com reports. The firm owned 108,637 shares of the biotechnology company’s stock after acquiring an additional 36,117 shares during the quarter. Curi RMB Capital LLC’s holdings in Iovance Biotherapeutics were worth $1,020,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. ORG Partners LLC acquired a new stake in shares of Iovance Biotherapeutics during the second quarter valued at about $32,000. Quest Partners LLC increased its position in shares of Iovance Biotherapeutics by 1,237.7% during the second quarter. Quest Partners LLC now owns 5,003 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 4,629 shares during the last quarter. EverSource Wealth Advisors LLC acquired a new stake in shares of Iovance Biotherapeutics during the second quarter valued at about $58,000. Daiwa Securities Group Inc. boosted its stake in shares of Iovance Biotherapeutics by 754.0% in the second quarter. Daiwa Securities Group Inc. now owns 8,813 shares of the biotechnology company’s stock valued at $71,000 after purchasing an additional 7,781 shares during the period. Finally, ORG Wealth Partners LLC purchased a new position in shares of Iovance Biotherapeutics in the third quarter valued at approximately $89,000. 77.03% of the stock is currently owned by institutional investors and hedge funds.

Iovance Biotherapeutics Trading Down 4.8 %

Shares of NASDAQ:IOVA opened at $8.18 on Friday. The company has a market capitalization of $2.49 billion, a PE ratio of -5.49 and a beta of 0.60. Iovance Biotherapeutics, Inc. has a twelve month low of $4.33 and a twelve month high of $18.33. The firm has a 50 day simple moving average of $10.04 and a 200-day simple moving average of $9.74.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.03. The business had revenue of $58.56 million during the quarter, compared to the consensus estimate of $53.54 million. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. During the same quarter in the previous year, the firm earned ($0.46) EPS. As a group, equities research analysts predict that Iovance Biotherapeutics, Inc. will post -1.25 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IOVA has been the subject of several recent research reports. StockNews.com raised shares of Iovance Biotherapeutics to a “sell” rating in a research note on Monday, August 12th. Piper Sandler lowered shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and lowered their price objective for the company from $19.00 to $10.00 in a research note on Monday, July 29th. UBS Group assumed coverage on shares of Iovance Biotherapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $17.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.33.

Insider Activity

In other news, Director Ryan D. Maynard sold 50,000 shares of Iovance Biotherapeutics stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total value of $503,000.00. Following the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $75,450. The trade was a 86.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 12.10% of the company’s stock.

Iovance Biotherapeutics Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.